Spravato

SPRAVATO® is an NMDA receptor antagonist believed to work differently from traditional antidepressants by acting on glutamate.

After you and your healthcare provider have decided SPRAVATO® is right for you – and you understand the benefits and risks – you can start planning for treatment.

• Your healthcare provider will work with you to determine if SPRAVATO® should be taken with or without an oral antidepressant

• For the first month, you'll take SPRAVATO® twice per week and then once per week for the second month. After the first month and throughout treatment, you and your healthcare provider will determine if SPRAVATO® should be continued and how often

• In a clinical study, SPRAVATO® taken alone was shown to significantly reduce depression symptoms at 4 weeks and at 24 hours compared to placebo

• If you’ve experienced an inadequate response to two or more antidepressants and have had intolerable side effects from oral antidepressants, SPRAVATO®taken alone may be an option for you

• Across clinical studies, patients on SPRAVATO® experienced low incidence of sexual dysfunction and weight gain compared to placebo

  • Sexual dysfunction and weight gain were not seen at a rate ≥2% and greater than placebo

• In a clinical study, ~90% of common side effects with SPRAVATO® that occurred on dosing day went away the same day of treatment

Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program.